• Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse 

      Guzmán, Eghon [Univ Mayor, Fac Med]; Arzeno, Lucas [Univ Mayor, Fac Med]; Aedo, Socrates; Villalon, Ricardo; Murray, Nigel P. (CANCER INTELLIGENCE LTD, 2019)
      Introduction: 25% of Stage III colon cancer patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery and chemotherapy. We hypothesise that sub-types of MRD, defined by circulating ...


      Modificado por: Sistema de Bibliotecas Universidad Mayor - SIBUM
      DSpace software copyright © 2002-2018  DuraSpace